vercirnon

Vercirnon is a novel, orally bioavailable small molecule anti-inflammatory agent that acts as a selective antagonist of the chemokine receptor CCR9. By binding to the intracellular side of CCR9, vercirnon exerts allosteric antagonism and prevents G-protein coupling, thereby inhibiting the migration of B and T lymphocytes to the gut. This mechanism is intended to reduce inflammation in inflammatory bowel diseases (IBD), particularly Crohn's disease and ulcerative colitis. Vercirnon was developed with an initial focus on Crohn's disease; however, pivotal phase III trials were suspended after failing to meet primary endpoints. Development for ulcerative colitis was also suspended, and no further development has been reported for celiac disease. The drug was originally developed by ChemoCentryx (now a subsidiary of Amgen) in collaboration with GlaxoSmithKline[1][2][5][6].

Brand names

Traficet-EN

Other names

GSK1605786GSK-1605786GSK 1605786vercirnon